Terpenes Under the Microscope: Dissecting Inconsistencies in State Cannabis Testing Programs and Their Impact on Patient Health

Terpenes Under the Microscope: Dissecting Inconsistencies in State Cannabis Testing Programs and Their Impact on Patient Health

The legalization of cannabis for medical purposes has revolutionized the healthcare landscape, offering patients a potential alternative for managing their health conditions. With over six million registered medical cannabis patients across the United States, state medical cannabis programs play a critical role in providing access to safe and effective medicine. However, ensuring the safety and quality of cannabis products remains a significant concern.

In a groundbreaking report titled “Regulating Patient Health: An Analysis of Disparities in State Cannabis Testing Programs,” Americans for Safe Access (ASA) dive deep into the inconsistencies and deficiencies found in cannabis testing programs across states, particularly related to other regulated products. Our primary focus is to shed light on the potential impact of these disparities on patient health and advocate for enhanced regulations and accurate labeling of cannabis products to safeguard public health.

ASA’s comprehensive analysis reveals significant inconsistencies in various aspects of cannabis testing programs. These include the types of tests required, the variety of contaminants tested for, the acceptable levels of contaminants, and the procedures for handling failed tests. Such disparities compromise the quality and safety of cannabis medicine available to patients and consumers.

For individuals with compromised immune systems, pediatric patients, or elderly patients on multiple medications, the presence of contaminants can have a profound impact on their health and safety. Inaccuracies in potency labeling and the homogeneity of cannabinoid ingredients can result in discomfort or debilitating symptoms that disrupt daily activities. It is alarming that many patients and consumers are unaware that their cannabis products may not be tested for the contaminants highlighted in our report.

Cannabis is susceptible to various contaminants, including microbiological contaminants like mold, E. Coli, Salmonella, and Aspergillus, as well as pesticides, heavy metals, residual solvents, additives, and adulterants. These contaminants can have serious health impacts, and consumers may find it challenging to trace symptoms back to cannabis products, especially when they believe they are using tested and regulated products.

To address these issues, state and federal policymakers play a crucial role in shaping and refining the regulatory framework surrounding cannabis testing. ASA urges policymakers to review the findings and recommendations presented in our report and actively contribute to the advancement of cannabis testing programs that prioritize patient health. It is essential to ensure the availability of safe, reliable, and effective cannabis products for those in need.

In light of their analysis, ASA calls upon state legislators to take action to improve their product safety and testing programs, including consumer education. Additionally, we urge policymakers to support the creation of the National Office of Medical Cannabis and Cannabinoid Control (OMCCC), which would collaborate with states in enhancing testing programs and, by extension, patient health.

The report provides a foundation for meaningful change in the cannabis market. We encourage everyone to explore the report, consider its implications, and join us in advocating for robust and uniform cannabis testing regulations. Together, we can create an environment where patients in every state can confidently access cannabis products that meet the highest standards of safety and quality.

Additional Resources:

Regulating Patient Health Executive Summary: This executive summary provides crucial information from our analysis.

Regulating Patient Health Full Report: Review or share the PDF copy of the complete report.

PFC Cannabis & Hemp Product Safety Standards: These standards ensure that cannabis products meet or exceed all relevant safety requirements, providing patients the quality they deserve.

A Legislative Proposal for Federal Guidance on Medical Cannabis and Cannabinoid Policy: Our report highlights the need for federal action and coordination to ensure safe cannabis products nationwide.

What’s in Your Cannabis Products? A Patient’s Guide to Understanding Labels and Interpreting Product Certificates of Analysis (CoA): This guide helps patients and consumers review cannabis product labels and analyses to ensure safe consumption.

(Note: The Sample Certificates of Analysis provided in the report were obtained from CannaSafe, a Patient Focused Certification (PFC) and ISO/IEC 17025 accredited laboratory located in Van Nuys, CA, with permission from their client KOI.)

Two key components highlighted in the provided sample certificates of analysis are the Cannabinoid Content and Terpene Content. The Cannabinoid Content section provides information on the product’s potency, indicating which cannabinoids have been detected and in what quantity. This information is crucial for patients to determine the exact dose they are taking and whether a specific cannabinoid, such as THC, is present in their product. Dosage information is typically presented in percentages by weight for flower products or in milligrams per gram or milligrams per milliliter for non-flower products like edibles or topicals.

The Terpene Content section identifies the presence of terpenes, which contribute to the flavors and scents of cannabis and may also contribute to the entourage effect—the idea that cannabinoids and terpenes work together synergistically to produce therapeutic effects.

By understanding the potency and terpene profiles of cannabis products, patients can make informed decisions about their medication and tailor their usage to suit their specific needs.

It is our hope that by addressing the disparities in cannabis testing programs, advocating for enhanced regulations, and educating patients and policymakers, we can create a safer and more reliable cannabis market that prioritizes patient health above all else.

Learn More About The Report: “Regulating Patient Health: An Analysis of Disparities in State Cannabis Testing Programs” at: https://www.safeaccessnow.org/whatsinyourcannabis

Follow on social media:

IG @americansforsafeaccess
@terpeneflashcards
Twitter @safeaccess

Feature Photo Courtesy of Jake W. – Romulan Genetics